On Thursday, in a major step forward in pain management, the U.S. Food and Drug Administration has approved a new nonopioid ...

Apple stock rises after the tech giant posts better-than-expected earnings and guides for solid growth, while Intel’s ...

Journavx is the first and only approved non-opioid oral painkiller and the first new class of pain medicine approved in more ...

Here’s what else you need to know to Get Up to Speed and On with Your Day. Three of President Donald Trump’s most controversial picks for his Cabinet and key administration roles were grilled during ...

Journavx is designed to eliminate the risks of addiction and overdose associated with medications like Vicodin and OxyContin.

Vertex Pharmaceuticals (VRTX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Terence ...

Barclays analyst Gena Wang raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $435 from $418 and keeps an Equal Weight rating ...

Shares of Vertex Pharmaceuticals rose 8% in off-hours trading after the pharmaceutical company won U.S. approval for the [first new non-opioid painkiller in decades]( ...

Vertex Pharmaceuticals' newly FDA-approved non-opioid analgesic, Journavx, offers a groundbreaking alternative for managing ...

The pharma major beat analysts' expectations in the fourth quarter of 2024, despite looming competition for its top heart drug Entresto. The watchdog blocked access to DeepSeek after the companies ...

The new drug type targets pathways in the peripheral nervous system before pain signals reach the brain, potentially lowering ...